Literature DB >> 28932528

First generation bioresorbable vascular scaffolds: do they hold the promise?

Islam Y Elgendy1, Ahmed N Mahmoud1, R David Anderson1.   

Abstract

Year:  2017        PMID： 28932528      PMCID： PMC5594108          DOI： 10.21037/jtd.2017.07.70

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  9 in total

1.  Bioresorbable Scaffolds versus Metallic Stents in Routine PCI.

Authors:  Joanna J Wykrzykowska; Robin P Kraak; Sjoerd H Hofma; Rene J van der Schaaf; E Karin Arkenbout; Alexander J IJsselmuiden; Joëlle Elias; Ivo M van Dongen; Ruben Y G Tijssen; Karel T Koch; Jan Baan; M Marije Vis; Robbert J de Winter; Jan J Piek; Jan G P Tijssen; Jose P S Henriques
Journal:  N Engl J Med       Date:  2017-03-29       Impact factor: 91.245

2.  Long-Term Safety of Drug-Eluting and Bare-Metal Stents: Evidence From a Comprehensive Network Meta-Analysis.

Authors:  Tullio Palmerini; Umberto Benedetto; Giuseppe Biondi-Zoccai; Diego Della Riva; Letizia Bacchi-Reggiani; Pieter C Smits; Georgios J Vlachojannis; Lisette Okkels Jensen; Evald H Christiansen; Klára Berencsi; Marco Valgimigli; Carlotta Orlandi; Mario Petrou; Claudio Rapezzi; Gregg W Stone
Journal:  J Am Coll Cardiol       Date:  2015-06-16       Impact factor: 24.094

3.  Outcomes With Intravascular Ultrasound-Guided Stent Implantation: A Meta-Analysis of Randomized Trials in the Era of Drug-Eluting Stents.

Authors:  Islam Y Elgendy; Ahmed N Mahmoud; Akram Y Elgendy; Anthony A Bavry
Journal:  Circ Cardiovasc Interv       Date:  2016-03-15       Impact factor: 6.546

4.  Does the Baseline Coronary Lesion Length Impact Outcomes With IVUS-Guided Percutaneous Coronary Intervention?

Authors:  Islam Y Elgendy; Ahmed N Mahmoud; Akram Y Elgendy; Anthony A Bavry
Journal:  J Am Coll Cardiol       Date:  2016-08-02       Impact factor: 24.094

5.  Long-Term Efficacy and Safety of Everolimus-Eluting Bioresorbable Vascular Scaffolds Versus Everolimus-Eluting Metallic Stents: A Meta-Analysis of Randomized Trials.

Authors:  Ahmed N Mahmoud; Amr F Barakat; Akram Y Elgendy; Erik Schneibel; Amgad Mentias; Ahmed Abuzaid; Islam Y Elgendy
Journal:  Circ Cardiovasc Interv       Date:  2017-05       Impact factor: 6.546

Review 6.  Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Metallic Stents.

Authors:  Sabato Sorrentino; Gennaro Giustino; Roxana Mehran; Anapoorna S Kini; Samin K Sharma; Michela Faggioni; Serdar Farhan; Birgit Vogel; Ciro Indolfi; George D Dangas
Journal:  J Am Coll Cardiol       Date:  2017-04-12       Impact factor: 24.094

7.  Long-Term Clinical Outcomes of Patients Treated With Everolimus-Eluting Bioresorbable Stents in Routine Practice: 2-Year Results of the ISAR-ABSORB Registry.

Authors:  Jens Wiebe; Petra Hoppmann; Roisin Colleran; Sebastian Kufner; Michael Valeskini; Salvatore Cassese; Simon Schneider; Michael Joner; Heribert Schunkert; Karl-Ludwig Laugwitz; Adnan Kastrati; Robert A Byrne
Journal:  JACC Cardiovasc Interv       Date:  2017-06-26       Impact factor: 11.195

Review 8.  Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.

Authors:  Salvatore Cassese; Robert A Byrne; Gjin Ndrepepa; Sebastian Kufner; Jens Wiebe; Janika Repp; Heribert Schunkert; Massimiliano Fusaro; Takeshi Kimura; Adnan Kastrati
Journal:  Lancet       Date:  2015-11-17       Impact factor: 79.321

9.  Sustained safety and performance of the second-generation drug-eluting absorbable metal scaffold in patients with de novo coronary lesions: 12-month clinical results and angiographic findings of the BIOSOLVE-II first-in-man trial.

Authors:  Michael Haude; Hüseyin Ince; Alexandre Abizaid; Ralph Toelg; Pedro Alves Lemos; Clemens von Birgelen; Evald Høj Christiansen; William Wijns; Franz-Josef Neumann; Christoph Kaiser; Eric Eeckhout; Soo Teik Lim; Javier Escaned; Yoshinobu Onuma; Hector M Garcia-Garcia; Ron Waksman
Journal:  Eur Heart J       Date:  2016-05-17       Impact factor: 29.983
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.